KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Acquisitions: 2018-2022

Historic Acquisitions for Amneal Pharmaceuticals (AMRX) over the last 4 years, with Dec 2022 value amounting to $84.7 million.

  • Amneal Pharmaceuticals' Acquisitions was N/A to $72.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $144.3 million, marking a year-over-year change of. This contributed to the annual value of $84.7 million for FY2022, which is 42.19% down from last year.
  • Amneal Pharmaceuticals' Acquisitions amounted to $84.7 million in FY2022, which was down 42.19% from $146.5 million recorded in FY2021.
  • In the past 5 years, Amneal Pharmaceuticals' Acquisitions ranged from a high of $324.6 million in FY2018 and a low of $84.7 million during FY2022.
  • Its 3-year average for Acquisitions is $160.9 million, with a median of $146.5 million in 2021.
  • Data for Amneal Pharmaceuticals' Acquisitions shows a maximum YoY slumped of 42.19% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Amneal Pharmaceuticals' Acquisitions stood at $324.6 million in 2018, then reached $251.4 million in 2020, then crashed by 41.70% to $146.5 million in 2021, then slumped by 42.19% to $84.7 million in 2022.